Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Cumulus Neuroscience
NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder
May 28, 2026
Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair
January 8, 2026
Cumulus Neuroscience Publishes Data Validating a Scalable Measurement of Neuroplasticity Using Low-Burden Dry Sensor EEG
January 6, 2026
Cumulus Neuroscience Presents Data at CTAD 2025 Annual Meeting
December 5, 2025